PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON
申请人:Obshchestvo S Ogranichennoy Otvetstvennostyou
"Fusion Pharma"
公开号:EP2743266A2
公开(公告)日:2014-06-18
The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.
本发明涉及借助新系列化合物治疗肿瘤、慢性炎症和类似疾病,这些化合物在抑制 Abl 激酶及其突变形式以及其他具有治疗意义的激酶方面具有更高的效率。它描述了通式(I)化合物和通式(II)化合物或其同分异构体、单个异构体、异构体混合物、药学上可接受的盐、溶液或水合物形式的蛋白激酶抑制剂。